RISK WATCHChartMill • 2d ago
Unusual Volume Standouts: Recent Session's High-Volume MoversUnusual volume scan: CETX fell 20.51%, BURU dropped 25.76%, SLGB rose 50.15%, and WKHS gained 13.33%, each with volume above 50-day averages.
Why LUNG Stock surged +25.60% Today — RQD Quant Desk Flash
$3.17 +25.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.31
Pulmonx Corporation (LUNG) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $135.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LUNG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LUNG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Pulmonx Corporation (NASDAQ: LUNG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.17 (+25.60% 1D, market cap $135.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LUNG ranks #715 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LUNG compare to SKYA and KRMD in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), LUNG carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -35.0%. By comparison, SKYA (SkyAI Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M) and KRMD (KORU Medical Systems Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -28.7%, cap $149.1M). Among the 5-stock peer group, LUNG leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LUNG?
▼
Per LUNG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001127537), Pulmonx Corporation generated $90.5M in revenue (+8.0% YoY), -$54.0M in net income, and -$32.8M in free cash flow against $129.3M in total assets and $37.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.31 (+4.42%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LUNG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY LUNG SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (37% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)
FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 77.1 (OVERBOUGHT (>70))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.84-3.3% Next Q
30
Q2 (-2Q)Grade E$1.78+2.8% Next Q
33
Q3 (-1Q)Grade E$1.83+73.2% Next Q
35
CurrentGrade D-$3.17-7.8% Hist 90D α
38
Trajectory: E (30) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LUNG Turnaround Squeeze
While LUNG currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.05) and Max Pain ($3.33) forces dealer call-delta covering toward $3.41.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LUNG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LUNG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LUNG Stock surged +25.60% Today — RQD Quant Desk Flash
Pulmonx Corporation (LUNG) surged +25.60% to $3.17, trading at 96% of its 52-week range ($1.13 – $3.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 96% of its 52-week range ($1.13 – $3.25) with RSI-14 at 77.1 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.17 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 74.2% gross margin and $0 annual free cash flow.
Live LUNG Headlines & Catalysts
CATALYSTYahoo • 2d ago
All You Need to Know About Pulmonx (LUNG) Rating Upgrade to BuyPulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MARKET WIREYahoo • 4d ago
Pulmonx to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will partic
MARKET WIREChartMill • 4d ago
US Top Movers: Biggest Gainers and Decliners in Today's SessionToday's US market movers: top gainers and decliners ranked by percentage change, with double-digit moves on both sides.
MARKET WIREChartMill • 4d ago
Oct. 28 Gap Stocks: Double-Digit Gap-Up and Gap-Down MoversOct. 28 gap movers: POM, BRAI, BOOM, LUNG and AXGN were among notable gap-up stocks, while BCAX, HUHU, SCKT, MKDW and MEGL posted steep gap-down declines.
MARKET WIREBenzinga • 4d ago
12 Health Care Stocks Moving In Wednesday's Intraday SessionGainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out yesterday.
CATALYSTBenzinga • 4d ago
Stifel Maintains Buy on Pulmonx, Raises Price Target to $4Stifel analyst Rick Wise maintains Pulmonx (NASDAQ:LUNG) with a Buy and raises the price target from $2.5 to $4.
MARKET WIREBenzinga • 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionGainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
MARKET WIREYahoo • 5d ago
Pulmonx (LUNG) Q3 2026 Earnings Call TranscriptRevenue returned to growth while losses narrowed significantly on cost discipline.
MARKET WIREYahoo • 5d ago
What Pulmonx (LUNG) Said on Its Q3 Earnings CallPulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to exp
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LUNG)
- ✓Walkthrough of LUNG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LUNG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +147.66%⚡ TESTING RESISTANCE
2026-10-30O $3.13H $3.23L $2.79C $3.17VOL 2.40M
RES: $3.26SUP: $1.83SMA50: $2.05SMA200: $1.66
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LUNG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LUNG today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LUNG. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LUNG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LUNG)
Health Care Rank #715 of 1016
⚔️ SKYA vs LUNG Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LUNG vs. SKYA, KRMD, PYPD, APYX)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pulmonx Corporation (LUNG) ranks #715 by composite RQD confidence (38/100, grade D-) and #621 by equity capitalization ($135.9M). Within this direct 5-issuer industry benchmark cohort, LUNG leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. KRMD currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with LUNG at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LUNG
ACTIVE
Pulmonx Corporation | D- | 38/100 | — | 74.2% | -35.0% | +25.60% | $135.9M | Benchmark Subject |
| SKYA SkyAI Inc. | D- | 36/100 | — | -30.0% | -35.0% | -0.68% | $126.7M | /skya-vs-lung → |
| KRMD KORU Medical Systems Inc. | D | 48/100 | — | 62.3% | -28.7% | +0.31% | $149.1M | /krmd-vs-lung → |
| PYPD PolyPid Ltd. | E | 33/100 | — | — | -35.0% | -3.29% | $113.5M | /pypd-vs-lung → |
| APYX Apyx Medical Corporation | E | 32/100 | — | 62.5% | -28.9% | +3.07% | $113.3M | /apyx-vs-lung → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001127537In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulmonx Corporation (LUNG) reported GAAP revenue of $90.5M (+8.0% vs. FY2024 revenue of $83.8M , and +31.8% cumulative change since FY2023) , GAAP net income of -$54.0M, operating cash flow of -$32.4M, and free cash flow of -$32.8M (+0.5% YoY). On the balance sheet, LUNG closed FY2025 with $129.3M in total assets against $37.0M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $90.5M | -$54.0M | -$32.4M | -$32.8M | $129.3M | $37.0M |
| FY2024 (FY) | 2024-12-31 | $83.8M | -$56.4M | -$31.5M | -$33.0M | $162.8M | $34.0M |
| FY2023 (FY) | 2023-12-31 | $68.7M | -$60.8M | -$37.6M | -$37.6M | — | — |
3. LUNG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LUNG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Pulmonx Corporation (NASDAQ: LUNG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.17 (+25.60% 1D, market cap $135.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LUNG ranks #715 in composite RQD confidence.
How does LUNG compare to SKYA and KRMD in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), LUNG carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -35.0%. By comparison, SKYA (SkyAI Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M) and KRMD (KORU Medical Systems Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -28.7%, cap $149.1M). Among the 5-stock peer group, LUNG leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LUNG?
Per LUNG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001127537), Pulmonx Corporation generated $90.5M in revenue (+8.0% YoY), -$54.0M in net income, and -$32.8M in free cash flow against $129.3M in total assets and $37.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LUNG trading relative to its 50-day, 200-day, and 52-week technical levels?
LUNG last traded at $3.17 (+25.60% on volume of 5,368,354 shares), positioning the stock +54.63% above its 50-day simple moving average ($2.05) and +90.96% above its 200-day simple moving average ($1.66). Across its 52-week range of $1.13 to $3.25, LUNG sits at the 96.2% percentile with a 14-day RSI of 77.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($2.77 to $3.57).
LUNG Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LUNG stock moving today?
Why LUNG Stock surged +25.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.